- Home
- MLAB vs REPL Comparison
MLAB vs REPL Comparison
Compare MLAB & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLAB
- REPL
- Stock Information
- Founded
- MLAB 1982
- REPL 2015
- Country
- MLAB United States
- REPL United States
- Employees
- MLAB N/A
- REPL N/A
- Industry
- MLAB Industrial Machinery/Components
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- MLAB Industrials
- REPL Health Care
- Exchange
- MLAB Nasdaq
- REPL Nasdaq
- Market Cap
- MLAB 680.0M
- REPL 649.1M
- IPO Year
- MLAB N/A
- REPL 2018
- Fundamental
- Price
- MLAB $100.12
- REPL $9.63
- Analyst Decision
- MLAB Hold
- REPL Strong Buy
- Analyst Count
- MLAB 2
- REPL 7
- Target Price
- MLAB $130.00
- REPL $20.29
- AVG Volume (30 Days)
- MLAB 41.8K
- REPL 1.7M
- Earning Date
- MLAB 05-28-2025
- REPL 05-22-2025
- Dividend Yield
- MLAB 0.63%
- REPL N/A
- EPS Growth
- MLAB N/A
- REPL N/A
- EPS
- MLAB N/A
- REPL N/A
- Revenue
- MLAB $240,978,000.00
- REPL N/A
- Revenue This Year
- MLAB $6.63
- REPL N/A
- Revenue Next Year
- MLAB $5.61
- REPL N/A
- P/E Ratio
- MLAB N/A
- REPL N/A
- Revenue Growth
- MLAB 11.47
- REPL N/A
- 52 Week Low
- MLAB $83.68
- REPL $4.93
- 52 Week High
- MLAB $155.12
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- MLAB 33.92
- REPL 58.72
- Support Level
- MLAB $98.06
- REPL $8.25
- Resistance Level
- MLAB $115.35
- REPL $10.16
- Average True Range (ATR)
- MLAB 5.61
- REPL 0.92
- MACD
- MLAB -2.05
- REPL 0.21
- Stochastic Oscillator
- MLAB 11.93
- REPL 84.04
About MLAB Mesa Laboratories Inc.
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in 4 divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.